Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

The Commercial Sickness Fund - KKH (hereinafter KKH) aims to conclude rebate contracts according to § 130a paragraph 8 SGB V with all suitable pharmaceutical companies for the active substance(s) within the framework of a so-called "Open-House procedure". Under the condition of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or accession to a rebate contract according to § 130a paragraph 8 SGB V for the active substance named in the tender. Interested pharmaceutical companies can request the participation documents and the contract from the contact address ([email protected]).